SPOTLIGHT: Pfizer to turn Esperion back to Newton

Pfizer snapped up Esperion Therapeutics four years ago, hip to its cholesterol candidates, but shut it down last year. Now, Esperion will relaunch as a private company with its previous leader, Roger Newton, at the helm. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.